Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis
出版年份 2021 全文链接
标题
Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis
作者
关键词
-
出版物
Cancers
Volume 13, Issue 11, Pages 2770
出版商
MDPI AG
发表日期
2021-06-02
DOI
10.3390/cancers13112770
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Downstaging of muscle invasive bladder cancer using neoadjuvant gemcitabine and cisplatin or dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as single-regimens or switch therapy modalities
- (2020) Andrew T. Ruplin et al. Clinical Genitourinary Cancer
- Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
- (2020) Thomas W. Flaig et al. Journal of the National Comprehensive Cancer Network
- Neoadjuvant Chemotherapy in Variant Histology Bladder Cancer: Current Evidence
- (2020) Siamak Daneshmand et al. European Urology Focus
- Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses
- (2020) Christian Pfister et al. EUROPEAN UROLOGY
- Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma
- (2020) Jianjun Gao et al. NATURE MEDICINE
- The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer
- (2019) Nikhil Waingankar et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies
- (2019) Andrea Necchi et al. EUROPEAN UROLOGY
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
- (2019) Thomas Powles et al. NATURE MEDICINE
- Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy
- (2018) Homayoun Zargar et al. JOURNAL OF UROLOGY
- A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).
- (2018) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer
- (2018) Charles C. Peyton et al. JAMA Oncology
- Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
- (2017) J. Alfred Witjes et al. EUROPEAN UROLOGY
- Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature
- (2017) Andrea Mari et al. WORLD JOURNAL OF UROLOGY
- Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis
- (2016) Ming Yin et al. ONCOLOGIST
- Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin
- (2015) Elisabeth E. Fransen van de Putte et al. WORLD JOURNAL OF UROLOGY
- Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity
- (2014) Elizabeth R. Plimack et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates
- (2014) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades
- (2013) Pascal Zehnder et al. BJU INTERNATIONAL
- The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses
- (2013) W.G. Melsen et al. CLINICAL MICROBIOLOGY AND INFECTION
- Correlation of Pathologic Complete Response with Survival After Neoadjuvant Chemotherapy in Bladder Cancer Treated with Cystectomy: A Meta-analysis
- (2013) Fausto Petrelli et al. EUROPEAN UROLOGY
- Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)
- (2012) A. Bamias et al. ANNALS OF ONCOLOGY
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial
- (2011) JOURNAL OF CLINICAL ONCOLOGY
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
- (2010) Andreas Stang EUROPEAN JOURNAL OF EPIDEMIOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started